UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an arthritis drug help fight pancreatic cancer?
Disease control Recruiting nowThis early-phase trial tests whether adding leflunomide (an arthritis drug) to standard chemotherapy gemcitabine is safe and effective for people with advanced pancreatic cancer that cannot be removed by surgery. About 19 adults will receive the combination to find the best dose …
Matched conditions: UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:11 UTC
-
New drug cocktail takes on tough pancreatic cancer
Disease control Recruiting nowThis early-stage trial tests a new targeted drug (CA-4948) added to standard chemotherapy for people with pancreatic cancer that has spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink tumors or slow the disease. About 43 adults w…
Matched conditions: UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New study peeks inside pancreatic tumors to find better drug targets
Knowledge-focused Recruiting nowThis study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers will give one of several drugs (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, or tremelimumab) for a short time before surgery or biopsy. By comparing tumor sampl…
Matched conditions: UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 16, 2026 23:47 UTC